Established by the end of 2000, ERIOCHEM is an argentine pharmaceutical company which specializes in the synthesis of active pharmaceutical ingredients, in the manufacturing of finished pharmaceutical products and the development of added value generics or supergenerics.

Dynamism and creativeness are the main aspects of our Research & Development Area.

Our highly qualified R&D team its devoted to the development of manufacturing processes of sustained release products, the production of active pharmaceutical ingredients, and oncological generics and supergenerics development.

It is ERIOCHEM’s policy to protect the intellectual property of its innovations: our main products are based on high-technology processes developed by ERIOCHEM for the most important international markets.

Our facilities are located in the countryside, only 16 km. away from the city of Paraná (Entre Ríos, Argentina), on a 10 has. land surface to ensure a safety ecological belt, with more than 8300 square meters covered by seven (7) plants and two (2) buildings for Quality Control activities.

Focused on pharmaceutical "sustained release products" based on biodegradable polymers and innovative high tech processes for the production of micro-spheres, ERIOCHEM uses its own techniques in the manufacturing processes of these products.

ERIOCHEM has two pharmaceutical plants for lyophilzed products for injection and injectables. “Plant 1”, where Acetato de Leuprolide Depot, Vinorelbine, Oxaliplatin and Docetaxel are manufactured, is approved by Argentina, MERCOSUR, INFARMED (Portugal), INVIMA (Colombia), MCC (South Africa), Belarus and was also successfully inspected by the German authorities.

Our new pharmaceutical “Plant 2” has a sterile area with quality “Class A” for lyophilized products and injectables, with automatic systems, cleaning in place and sterilization in place, which guarantee complete aseptic proceses and products, with the aim of obtaining its future approval by the FDA. Up to now is already approved by Argentina, MERCOSUR, INVIMA (Colombia), MCC (South Africa), Belarus and was also successfully inspected by the German authorities.


Integrative processes make ERIOCHEM a reliable and solid supplier, as we are manufacturers of our own raw materials and essential intermediates. This vertical production strategy assures us and our partners the supply of the main ingredients of our processes.

Vinorelbine’s manufacture is made from the agricultural stage, as ERIOCHEM owns “Catharanthus roseus” plantations in Argentina.
Vinorelbine is sold by ERIOCHEM in the most demanding markets worldwide.
APIs: we offer technological and scientific skills. Our use of state-of-the-art technology enables us to meet all currently accepted industrial and marketing standards. By consistently complying with these standards, we have positioned ourselves as a reliable and innovative partner for many of the world’s leading pharmaceutical companies. Our aim is to establish with our partners lasting relationships based on dedication and mutual trust.
ERIOCHEM Pharmochemical Plant produces also Oxaliplatin, Melphalan and Polymers for Microcapsulation: Poly (lactic-glycolic) acid 75:25 (PLGA) and Polylactic acid (PLA). Our Pramochemical Plant was inspected and approved by ANMAT - PIC (Argentina), FDA (USA), EMEA,INFARMED (Portugal), BfArM (Germany), TGA (Australia), KFDA (Korea) and MCC (South Africa).

Best partners for excellent products: our products are distributed by the most important pharmaceutical companies of each region:

SANDOZ of Novartis Group for Latin America and Asia.
KALBE PHARMACEUTICALS in Asia-Pacífic.
HOSPIRA in Australia, New Zealand, USA, Canada and Europe.
TEVA in Latin America and Europe.
MYLAN in Europe, Japan and Asia